Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.

The separation and biological evaluation of rotamers as well as interconversion studies on rotamers of our clinical candidate SCH 351125 are described.

[1]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[2]  Pink,et al.  Atropisomeric amides as chiral ligands: using (-)-sparteine-directed enantioselective silylation to control the conformation of a stereogenic axis , 2000, The Journal of organic chemistry.

[3]  P. Murphy.  Viral exploitation and subversion of the immune system through chemokine mimicry , 2001, Nature Immunology.

[4]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[5]  W. Greenlee,et al.  Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. , 2001, Journal of medicinal chemistry.

[6]  J. Moore,et al.  Viral phenotype and CCR5 genotype , 1999, Nature Medicine.

[7]  G. Larosa,et al.  Chapter 26 – Chemokine Receptors As HIV Co-Receptors: Targets for Therapeutic Intervention in AIDS , 1998 .

[8]  C. Supuran,et al.  Small molecule antagonists of chemokine receptors as emerging anti-HIV agents , 2001 .

[9]  C. Supuran,et al.  Non-peptidic Chemokine Receptors Antagonists as Emerging Anti-HIV Agents , 2002, Journal of enzyme inhibition and medicinal chemistry.

[10]  J. Mascola,et al.  The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression , 1997, Nature Medicine.

[11]  J. Saunders,et al.  Opportunities for novel therapeutic agents acting at chemokine receptors. , 1999, Drug discovery today.

[12]  W. Greenlee,et al.  Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. , 2002, Journal of medicinal chemistry.

[13]  J. Moore,et al.  HIV-1 entry inhibitors: Evading the issue , 1999, Nature Medicine.

[14]  D. Curran,et al.  Synthesis of enantioenriched axially chiral anilides from atropisomerically enriched tartarate ortho-anilides. , 2001, Journal of the American Chemical Society.

[15]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[16]  A. Fujishima,et al.  Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements. , 1998, Journal of medicinal chemistry.

[17]  D. Littman.  Chemokine Receptors: Keys to AIDS Pathogenesis? , 1998, Cell.

[18]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[19]  Serena Xu,et al.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.